Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Jul 15, 2015Boston Scientific Corporation (NYSE: BSX) announces the election of Donna A. James to its board of directors, effective immediately. Donna A. James is the founder and managing director of Lardon &...
Jul 9, 2015Boston Scientific Corporation (NYSE: BSX) announces that Bronchial Thermoplasty (BT) delivered by the Alair™ System has received support from the American College of Allergy, Asthma and...
Jul 1, 2015Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2015 on Thursday, July 23, 2015 at
Jun 22, 2015Boston Scientific (NYSE: BSX) has initiated a worldwide study to evaluate the rate and causes of shocks for patients implanted with the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) for...
Jun 10, 2015Boston Scientific Corporation (NYSE: BSX) presented new data demonstrating that the Precision Spectra™ Spinal Cord Stimulator (SCS) System provided 1.5 times better overall pain relief and 2...
Jun 4, 2015World's Smallest 16-Contact High-Capacity Primary Cell Device Expands Spinal Cord Stimulator System OfferingBoston Scientific announces the European launch of the Precision Novi™ Spinal Cord Stimulator (SCS) System at the International Neuromodulation Society in Montreal, Canada. The 16-contact...
May 26, 2015Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Goldman Sachs 36th Annual Global Healthcare Conference on June 9 in Rancho Palos Verdes, CA. Dan Brennan, executive...
May 20, 2015Compelling Results Presented at EuroPCR 2015 Add to Growing Body of Evidence Supporting Performance and SafetyA new study evaluating the Boston Scientific (NYSE: BSX) Lotus™ Valve System demonstrated an extremely low rate of paravalvular aortic regurgitation (leakage) for a transcatheter aortic...
May 19, 2015Additional Data from EVOLVE II Pivotal Trial Demonstrate Safety and Performance in Patients with Diabetes at One YearBoston Scientific (NYSE: BSX) reported positive, long-term data from the EVOLVE Trial of the SYNERGY™ Everolimus-Eluting Bioabsorbable Polymer Platinum Chromium Coronary Stent System, with no...
May 12, 2015Boston Scientific Corporation (NYSE: BSX) completed a public offering of $1.85 billion aggregate principal amount of its senior notes under the company's shelf registration statement. The public...